Rusnano will save Americans from alcohol poisoning

The Russian fund invested in the American technology of treatment of metabolism

LLC "Marchmont Capital partners"The venture fund "RosnanoMedInvest", one of the portfolio funds of "Rusnano", has invested in the American Aldea Pharmaceuticals, which develops drugs for the treatment of metabolic disorders, according to the company's website (Aldea Pharmaceuticals Closes $24 Million Series B Financing).

RosnanoMedInvest led a round of investments totaling $ 24 million. In addition to the Russian fund, another new investor joined the deal – WuXi PharmaTech Corporate Ventures, a corporate fund of the Chinese company WuXi PharmaTech. Aldea's current investors, including Canaan Partners and Correlation Ventures, have also invested in the startup.

Aldea Pharmaceuticals is developing drugs for the treatment of aldehyde metabolism disorders. The raised funding will be used to organize clinical trials of the drug AD-6626, designed to help patients with acute alcohol intoxication. It is assumed that this tool will be used in emergency departments.

In addition, Aldea Pharmaceuticals will invest in testing a drug for the treatment of Fanconi anemia. This rare genetic disease is accompanied by increased fragility of chromosomes and often leads to cancer.

Aldea Pharmaceuticals, founded in 2011, is based in Redwood City, California. The company's developments are based on scientific research conducted at Stanford University.

Portal "Eternal youth" http://vechnayamolodost.ru04.09.2014